Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
-
REGULATORY MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
-
BUSINESS Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
-
REGULATORY MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
-
REGULATORY MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
-
BUSINESS New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
-
ORGANIZATION New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
-
BUSINESS Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
-
BUSINESS Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
-
REGULATORY Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
-
REGULATORY FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
-
REGULATORY FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
-
BUSINESS Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
-
REGULATORY Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
-
ACADEMIA Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
-
BUSINESS Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
-
REGULATORY Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
-
ACADEMIA Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
-
REGULATORY No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
-
BUSINESS AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…